PARP Inhibition | sciencenewsnet.in

Breaking News

Structural Safety Monitoring of Buildings with Color Variations

Out of Africa: UT Southwestern cardiologist gets to the heart of Zambia’s No. 1 health threat

Weight loss interventions associated with improvements in several symptoms of PCOS

Policies assuring safe practice by late-career physicians vary widely among health care organizations

Researchers report first published case of a patient with treatment-emergent neuroendocrine prostate cancer who showed a remarkable response to an anti-HER2 antibody-drug conjugate

Patients outside metropolitan areas often travel significantly more than 20 minutes for primary care visit

Discovery of a protein’s key role in RNA processes could improve disease treatment in humans and plants

Health Research Launches Into Orbit to Discover How Spaceflight Affects Blood

Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University

Gastrointestinal Surgeon Fabrizio Michelassi, MD, FACS, Elected Chair of ACS Board of Regents

05 Nov, 2024

Revolutionizing Ovarian Cancer Treatment With Adaptive PARP Inhibitor Therapy

June 26, 2024 sarah JonasResearch Results

A new study led by researchers at Moffitt Cancer Center introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. Their work is featured as the cover article of the June 19 issue of Cell Systems.

AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects

April 8, 2024 sarah JonasResearch Results

The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.